US Stock MarketDetailed Quotes

CMMB Chemomab Therapeutics

Watchlist
  • 1.930
  • +0.070+3.76%
Trading Aug 29 13:36 ET
35.72MMarket Cap-1820P/E (TTM)

Chemomab Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chemomab Therapeutics Q2 2024 Earnings Date

Currency：USDAug 21, 2024

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
0
0
0
--
--
--
EPS
-<0.01
-0.26
-0.25
Miss Est.
+72.42%
+63.89%
-2526.26%
Analyst Rating
Strong Buy

Jul 31, 2024

Chemomab Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 0.000--
--2024/Q3-- / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
Mar 7, 20242023/Q40.000 / 0.000--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 0.000--
--2024/Q3-- / 0.000--
Aug 21, 20242024/Q20.000 / 0.000--
May 9, 20242024/Q10.000 / 0.000--
Mar 7, 20242023/Q40.000 / 0.000--

Unlock Free Earnings Estimates

Chemomab Therapeutics Earnings Reports

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Aug 21 07:05 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    Jul 25 08:13 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    May 9 07:02 ET

  • Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

    May 3 16:07 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Jul 31, 2024

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg
    Concept Top Gainers Yesterday
    Top Gainers Yesterday
    Intraday+0.49%